Schved J-F
Département d'hématologie biologique, hôpital Saint-Éloi, CHU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France.
Transfus Clin Biol. 2015 Aug;22(3):85-9. doi: 10.1016/j.tracli.2015.03.006. Epub 2015 Apr 29.
Until 1990, congenital hemorrhagic disorders were treated by plasma-derived concentrates. The first recombinant drug, recombinant factor VIII was available after this date and few years later recombinant factor IX could also be proposed to patients. The evolution of market share in France was different between these two drugs: while recombinant factor VIII took a large place in hemophilia A treatment (85%), plasma-derived factor IX represent 50% of the French market. In the next years, the arrival of long-acting antihemophilic factors may lead to the dramatically reduce the amount of plasma-derived antihemophilic factors used to treat hemophilia. For rare bleeding coagulation disorders, plasma-derived concentrates are still widely used, while they are the only concentrates available in most diseases. This situation is unlikely to evolve significantly in the next years.
直到1990年，先天性出血性疾病一直通过血浆源性浓缩物进行治疗。在此日期之后，第一种重组药物重组凝血因子VIII问世，几年后重组凝血因子IX也可供患者使用。这两种药物在法国的市场份额演变情况有所不同：虽然重组凝血因子VIII在A型血友病治疗中占据了很大份额（85%），但血浆源性凝血因子IX占法国市场的50%。在接下来的几年里，长效抗血友病因子的出现可能会导致用于治疗血友病的血浆源性抗血友病因子用量大幅减少。对于罕见的出血性凝血障碍，血浆源性浓缩物仍被广泛使用，而在大多数疾病中它们是唯一可用的浓缩物。这种情况在未来几年不太可能有显著变化。
